J&J COVID-19 booster found to cut omicron hospitalizations in South African study
Headline from FOX 5 New York
Johnson & Johnson’s COVID-19 booster shot was found to reduce the risk of omicron-related hospitalization by about 85%, according to a South African clinical trial.
FOX 5 New York's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Johnson & Johnson’s COVID-19 booster shot was found to reduce the risk of omicron-related hospitalization by about 85%, according to a South African clinical trial.
Johnson & Johnson's booster shot provides high levels of protection against the omicron variant of Covid-19, according to data from a trial of healthcare workers in South Africa released Thursday
By Maggie Fox, CNN Two reports released Thursday show that people who get booster doses of Johnson & Johnson’s Janssen vaccine are well protected against severe disease and hospitalization from the Omicron variant of coronavirus, the company said.
Johnson & Johnson's booster provides strong protection against the omicron variant of Covid-19, according to a trial of healthcare workers in South Africa.
A preliminary South African government study published Thursday showed a booster of the Johnson & Johnson Covid vaccine was 85 percent effective in preventing hospitalization from the Omicron variant…
Two reports released Thursday show that people who get booster doses of Johnson & Johnson vaccine are well protected against severe disease and hospitalization from the omicron variant, the company said.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
J&J COVID-19 booster found to cut omicron hospitalizations in South African study | Since Then